Publicacións nas que colabora con María Covadonga Martínez Díaz Caneja (18)

2023

  1. Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: The OPTiMiSE study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3471-3479

  2. Neighborhood Vulnerability and Disability in First Episode of Psychosis: A Multilevel Study

    The Journal of clinical psychiatry, Vol. 84, Núm. 2

  3. Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120

2022

  1. Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia

    Schizophrenia Research, Vol. 243, pp. 32-42

  2. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1

  3. The effect of early life events on glucose levels in first-episode psychosis

    Frontiers in Endocrinology, Vol. 13

  4. The relationship between negative symptoms, social cognition, and social functioning in patients with first episode psychosis

    Journal of Psychiatric Research, Vol. 155, pp. 171-179

2021

  1. How does neighbourhood socio-economic status affect the interrelationships between functioning dimensions in first episode of psychosis? A network analysis approach

    Health and Place, Vol. 69

  2. Premorbid Characteristics as Predictors of Early Onset Versus Adult Onset in Patients with a First Episode of Psychosis

    Journal of Clinical Psychiatry, Vol. 82, Núm. 6

  3. The interplay between functioning problems and symptoms in first episode of psychosis: An approach from network analysis

    Journal of Psychiatric Research, Vol. 136, pp. 265-273

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294

  2. Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning

    European Neuropsychopharmacology, Vol. 34, pp. 76-86

  3. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

  2. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

  3. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

    Psychological Medicine, Vol. 48, Núm. 13, pp. 2247-2256

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

2014

  1. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra

    Revista de Psiquiatria y Salud Mental, Vol. 7, Núm. 4, pp. 166-178